Erythro-9-(2-hydroxy-3-nonyl)adenine alone and in combination with 9-β-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in mice

W. M. Shannon, G. Arnett, F. M. Schabel, T. W. North, S. S. Cohen

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Although the antiviral activity of erythro-9-(2-hydroxy-3-nonyl)adenine, a potent adenosine deaminase inhibitor, against herpes simplex virus type 1 in cell culture was readily confirmed, the compound was found to be totally ineffective in the treatment of experimentally induced systemic herpes simplex virus type 1 infections in Swiss mice. Data was obtained, however, which clearly indicated that the antiviral potency of 9-β-D-arabinofuranosyladenine in vivo could be enhanced by the co-administration of low, nontoxic doses of erythro-9-(2-hydroxy-3-nonyl)adenine.

Original languageEnglish (US)
Pages (from-to)598-603
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume18
Issue number4
StatePublished - 1980
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Erythro-9-(2-hydroxy-3-nonyl)adenine alone and in combination with 9-β-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in mice'. Together they form a unique fingerprint.

  • Cite this